NASDAQ:DBVT

DBV Technologies (DBVT) Stock Forecast, Price & News

$1.96

+0.02 (+0.77%)

(As of 02:32 PM ET)

Compare

Today's Range: $1.91
▼
$2.00
50-Day Range: $1.42
▼
$2.23
52-Week Range: $1.08
▼
$3.43

Volume: 50,847 shs
Average Volume: 92,792 shs
Market Capitalization: $369.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.67

DBV Technologies MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 245.4% Upside
$6.67 Price Target
Short Interest: Bearish
0.91% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.51) to ($0.47) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.41 out of 5 stars

Medical Sector

1877th out of 1,980 stocks

Biological Products, Except Diagnostic Industry

313th out of 330 stocks

3.3

Analyst's Opinion

Consensus Rating
DBV Technologies has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $6.67, DBV Technologies has a forecasted upside of 245.4% from its current price of $1.93.
Amount of Analyst Coverage
DBV Technologies has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
0.91% of the outstanding shares of DBV Technologies have been sold short.
Short Interest Ratio / Days to Cover
DBV Technologies has a short interest ratio ("days to cover") of 24.7, which indicates bearish sentiment.
Change versus previous month
Short interest in DBV Technologies has recently increased by 2.40%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
DBV Technologies does not currently pay a dividend.
Dividend Growth
DBV Technologies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DBVT.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for DBV Technologies this week, compared to 2 articles on an average week.
MarketBeat Follows
1 people have added DBV Technologies to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, DBV Technologies insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.71% of the stock of DBV Technologies is held by insiders.
Percentage Held by Institutions
Only 18.37% of the stock of DBV Technologies is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for DBV Technologies are expected to grow in the coming year, from ($0.51) to ($0.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of DBV Technologies is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of DBV Technologies is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
DBV Technologies has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About DBV Technologies (NASDAQ:DBVT) Stock

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Receive DBVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

DBVT Stock News Headlines

May 26, 2023 | americanbankingnews.com

DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

May 20, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)

June 1, 2023 | Edge On The Street (Ad)

AI Getting Close to Thinking Like Humans

Technology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.

May 13, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for DBV Technologies S.A. Lowered by HC Wainwright (NASDAQ:DBVT)

May 12, 2023 | finance.yahoo.com

A simple skin patch shows promise for preventing peanut allergies

May 12, 2023 | americanbankingnews.com

HC Wainwright Comments on DBV Technologies S.A.'s FY2026 Earnings (NASDAQ:DBVT)

May 11, 2023 | marketwatch.com

DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin(TM) Peanut in Toddlers

May 11, 2023 | markets.businessinsider.com

Good News For Toddlers With Peanut Allergy: DBVT Data Shows Promising Results for Peanut Allergy Patch

June 1, 2023 | Edge On The Street (Ad)

ChatGPT Is Already "Old School"

As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.

May 11, 2023 | americanbankingnews.com

DBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.com

May 11, 2023 | markets.businessinsider.com

JMP Securities Sticks to Its Buy Rating for DBV Technologies SA – American (DBVT)

May 10, 2023 | finance.yahoo.com

DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers

May 10, 2023 | americanbankingnews.com

DBV Technologies S.A. (NASDAQ:DBVT) Receives $6.67 Average PT from Brokerages

May 9, 2023 | markets.businessinsider.com

DBV Technologies SA – American (DBVT) Gets a Buy from H.C. Wainwright

May 5, 2023 | markets.businessinsider.com

JMP Securities Keeps Their Buy Rating on DBV Technologies SA – American (DBVT)

May 4, 2023 | finance.yahoo.com

DBV Technologies Reports First Quarter 2023 Financial Results

April 30, 2023 | americanbankingnews.com

Solid Biosciences (NASDAQ:SLDB) vs. DBV Technologies (NASDAQ:DBVT) Critical Comparison

April 20, 2023 | marketwatch.com

DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 - 3 Years After Receiving Pre-BLA Responses from FDA

April 19, 2023 | finanznachrichten.de

DBV Technologies S.A.: DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 - 3 Years After Receiving Pre-BLA Responses from FDA

April 19, 2023 | finance.yahoo.com

DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA

April 17, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

April 13, 2023 | americanbankingnews.com

Brokerages Set DBV Technologies S.A. (NASDAQ:DBVT) Target Price at $6.67

April 12, 2023 | finanznachrichten.de

DBV Technologies S.A.: DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

April 12, 2023 | finance.yahoo.com

DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

April 9, 2023 | americanbankingnews.com

DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

March 24, 2023 | finance.yahoo.com

Ordinary and Extraordinary General Meeting of April 12, 2023

March 13, 2023 | finance.yahoo.com

DBV Technologies Update

See More Headlines

DBVT Price History

30 days | 90 days | 365 days | Advanced Chart

DBVT Company Calendar

Last Earnings: 5/04/2023
Today: 6/01/2023
Next Earnings (Estimated): 8/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DBVT
CUSIP: N/A
CIK: 1613780
Web: www.dbv-technologies.com
Phone: (315) 542-7878
Fax: 33-1-43-26-10-83
Employees: 92
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.67
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +241.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-96,270,000.00
Net Margins: -778.60%
Pretax Margin: -2,228.93%
Return on Equity: -48.25%
Return on Assets: -39.56%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.41
Quick Ratio: 6.41

Sales & Book Value

Annual Sales: $4.84 million
Price / Sales: 75.85
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.95 per share
Price / Book: 2.05

Miscellaneous

Outstanding Shares: 188,270,000
Free Float: 187,144,000
Market Cap: $367.13 million
Optionable: Optionable
Beta: 1.27

Key Executives

Daniel Tassé
Chief Executive Officer & Executive Director

Sébastien Robitaille
Chief Financial Officer

Pharis Mohideen
Chief Medical Officer

Pascal Wotling
Chief Technical Operations & Quality Officer

Pascale Ehouarn
Chief Engineering, Manufacturing & Supply Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

DBVT Stock - Frequently Asked Questions

Should I buy or sell DBV Technologies stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DBVT shares.
View DBVT analyst ratings or view top-rated stocks.
What is DBV Technologies' stock price forecast for 2023?: 5 brokers have issued 1-year price objectives for DBV Technologies' stock. Their DBVT share price forecasts range from $4.00 to $10.00. On average, they predict the company's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 241.9% from the stock's current price.
View analysts price targets for DBVT or view top-rated stocks among Wall Street analysts.
How have DBVT shares performed in 2023?: DBV Technologies' stock was trading at $1.53 at the beginning of 2023. Since then, DBVT stock has increased by 27.5% and is now trading at $1.95.
View the best growth stocks for 2023 here.
When is DBV Technologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our DBVT earnings forecast.
How were DBV Technologies' earnings last quarter?: DBV Technologies S.A. (NASDAQ:DBVT) issued its quarterly earnings results on Thursday, May, 4th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.14. The company earned $2.19 million during the quarter, compared to analyst estimates of $1.30 million. DBV Technologies had a negative net margin of 778.60% and a negative trailing twelve-month return on equity of 48.25%.
What other stocks do shareholders of DBV Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO).

What is DBV Technologies' stock symbol?: DBV Technologies trades on the NASDAQ under the ticker symbol "DBVT."
Who are DBV Technologies' major shareholders?: DBV Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include Ameriprise Financial Inc. (0.64%), BlackRock Inc. (0.52%) and OLD Mission Capital LLC (0.02%).
How do I buy shares of DBV Technologies?: Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is DBV Technologies' stock price today?: One share of DBVT stock can currently be purchased for approximately $1.95.
How much money does DBV Technologies make?: DBV Technologies (NASDAQ:DBVT) has a market capitalization of $367.13 million and generates $4.84 million in revenue each year. The company earns $-96,270,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.
How can I contact DBV Technologies?: DBV Technologies' mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The official website for the company is www.dbv-technologies.com. The company can be reached via phone at (315) 542-7878, via email at sara.sherman@dbv-technologies.com, or via fax at 33-1-43-26-10-83.

This page (NASDAQ:DBVT) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial